The PD-L1-mTOR intersection in tumor migration and invasion.
4 affiliations
- 1Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil. [email protected].
- 2Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
- 3Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
- 4Department of Pharmacology, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto, Alegre, RS, Brazil.
Abstract
Programmed death-ligand 1 (PD-L1) has emerged as an important player in intrinsic tumor cell biology besides its canonical immune checkpoint function. Cumulative experimental data points to a role for PD-L1 in promoting and maintaining an invasive cell phenotype within different cancer cells through its interaction with mechanistic target of rapamycin (mTOR) signaling. In this review, we summarize the main experimental data pointing to the PD-L1/mTOR interaction in tumor cell invasion capacity both in vitro and in vivo. In this crosstalk, PD-L1 expression is induced by IFN-γ/STAT1 and IL-6/STAT3 pathways, as well as mTOR activity by its upstream effectors like EGFR and other tyrosine kinase receptor ligands. Interestingly, PD-L1 itself seems to play a role in mTOR activation. In many of these models, the PD-L1 importance in cell migration capacity is evidenced by two major observations: (1) its knockout impairs cell invasion capacity and, (2) its upregulation is associated with increased cell migration and both the induction and maintenance of epithelial-mesenchymal transition (EMT) phenotype markers, such as increased N-cadherin and ZEB1 and decreased E-cadherin. We also summarize the main clinical trials combining mTOR pathway inhibitors with anti-PD-L1 antibodies in different cancer types.
Related
- Extracellular adenosine triphosphate upregulates S100A4 expression and promotes the migration and invasion of breast cancer cells via P2Y2/SOX9 signaling
- Targeting neuronal pentraxin 1 microRNA-492 exerts pro-tumorigenic effects in colorectal cancer through stimulation of proliferation, migration, and invasion
- Repositioning of cis-flupentixol for the suppression of ovarian cancer cell migration and invasion through ERK5 inhibition
- Identification and validation of NCOA5-ZCCHC3/FGF22 axis as a prognostic marker in lung adenocarcinoma migration and invasion.
- Study on the promoting effect of microplastic exposure on prostate cancer migration and invasion based on network toxicology and single-cell sequencing technology
BibTeX
@article{palavro2026pdl1mtor,
title = {{The PD-L1-mTOR intersection in tumor migration and invasion.}},
author = {Rafael Palavro and Thales Thor Ramos Previato and Douglas Bottega Pazzin and Júlia Budelon Gonçalves and Marina Ottmann Boff and Daniel Marinowic and Jaderson Costa da Costa and Thamiris Becker Scheffel},
journal = {Molecular biology reports},
year = {2026},
month = oct,
doi = {10.1007/s11033-026-12982-6},
url = {https://europepmc.org/article/MED/42909562},
note = {CC BY},
}
RIS
TY - JOUR
TI - The PD-L1-mTOR intersection in tumor migration and invasion.
AU - Rafael Palavro
AU - Thales Thor Ramos Previato
AU - Douglas Bottega Pazzin
AU - Júlia Budelon Gonçalves
AU - Marina Ottmann Boff
AU - Daniel Marinowic
AU - Jaderson Costa da Costa
AU - Thamiris Becker Scheffel
PY - 2026
DA - 2026/10/23
JO - Molecular biology reports
DO - 10.1007/s11033-026-12982-6
UR - https://europepmc.org/article/MED/42909562
AB - Programmed death-ligand 1 (PD-L1) has emerged as an important player in intrinsic tumor cell biology besides its canonical immune checkpoint function. Cumulative experimental data points to a role for PD-L1 in promoting and maintaining an invasive cell phenotype within different cancer cells through its interaction with mechanistic target of rapamycin (mTOR) signaling. In this review, we summarize the main experimental data pointing to the PD-L1/mTOR interaction in tumor cell invasion capacity both in vitro and in vivo. In this crosstalk, PD-L1 expression is induced by IFN-γ/STAT1 and IL-6/STAT3 pathways, as well as mTOR activity by its upstream effectors like EGFR and other tyrosine kinase receptor ligands. Interestingly, PD-L1 itself seems to play a role in mTOR activation. In many of these models, the PD-L1 importance in cell migration capacity is evidenced by two major observations: (1) its knockout impairs cell invasion capacity and, (2) its upregulation is associated with increased cell migration and both the induction and maintenance of epithelial-mesenchymal transition (EMT) phenotype markers, such as increased N-cadherin and ZEB1 and decreased E-cadherin. We also summarize the main clinical trials combining mTOR pathway inhibitors with anti-PD-L1 antibodies in different cancer types.
SN - 0301-4851
SN - 1573-4978
ER -